NCT07327684 Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity
| NCT ID | NCT07327684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Insulin Resistance |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-05-22 |
| Primary Completion | 2026-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this study is to develop a novel, non-invasive, real-time photoacoustic imaging (PAI) technology for quantifying brown adipose tissue (BAT) and to investigate the differences in BAT morphology and metabolic function between healthy individuals and patients with metabolic syndrome. The main questions it aims to answer are: 1. Can PAI technology quantify BAT metabolic function and establish standardized PAI parameters for BAT assessment? 2. Can PAI parameters distinguish the BAT characteristics of healthy volunteers from patients with metabolic syndrome? Both healthy adults and patients diagnosed with metabolic syndrome will be recruited. Participants will undergo PAI scans of BAT region under normal conditions and after cold exposure to assess BAT activation. The ultimate goal is to validate this radiation-free PAI method as a convenient and effective tool for evaluating BAT metabolism, potentially aiding in early diagnosis and treatment monitoring of metabolic syndrome.
Eligibility Criteria
Criteria for Healthy Subjects: (INCLUSION CRITERIA) 1. Healthy individuals over 18 years of age. 2. Body Mass Index (BMI) \< 30. 3. No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases. 4. Not currently using any sympathomimetic or sympatholytic drugs. 5. Non-smoker and does not consume excessive alcohol. (EXCLUSION CRITERIA) 1. Weight change \> 5% within 3 months prior to enrollment. 2. BMI ≥ 30. 3. Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular and cerebrovascular disease, or malignant tumor. 4. Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment. 5. Smoker or consumes excessive alcohol. 6. Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation. 7. Currently pregnant, lactating, or menstruating. 8. Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination. Criteria for